HUTCHMED announces new and updated data from studies to be presented at the 2025 World Conference on Lung Cancer and the Chinese Society of Clinical Oncology Annual Meeting. Data from savolitinib studies in NSCLC patients will be highlighted at WCLC 2025. Additionally, clinical data on HMPL-653 in patients with tenosynovial giant cell tumor will be presented at the CSCO Annual Meeting 2025. The company focuses on the discovery and development of targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines already marketed in China.

The 2025 World Conference on Lung Cancer will feature presentations on the efficacy and safety of savolitinib in METex14 NSCLC patients, frontline treatment duration in MET-Amplified NSCLC, and more. The Chinese Society of Clinical Oncology Annual Meeting will showcase a phase I study of HMPL-653 in patients with tenosynovial giant cell tumor. HUTCHMED is dedicated to advancing therapies for cancer and immunological diseases, with a strong focus on bringing innovative drug candidates from discovery to patients globally.

Read more at GlobeNewswire: HUTCHMED Highlights Clinical Data to be Presented at the